Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

May 31, 2015

Conditions
Hypertension
Interventions
DRUG

GROUP A: Valsartan plus Chlorthalidone

Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.

DRUG

GROUP B: Valsartan

GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.

DRUG

GROUP C: Chlorthalidone

GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.

Trial Locations (8)

11001

MedPlus, Bogota DC

130001

Centro de Diagnostico Cardiologico, Cartagena

630001

Fundacion Cardiomet Cequin, Armenia

EC170150

Centro AMCOR, Quito

Centro Clinico quirurgico, Quito

Centro médico de hipertensión arterial, Quito

Clínica DAME, Quito

Consultorio Edificio Novoa, Quito

All Listed Sponsors
lead

Farma de Colombia SA

INDUSTRY

NCT01850160 - Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension | Biotech Hunter | Biotech Hunter